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ABSTRACT
Prebiotic oligosaccharides are used as supplements to improve colon health. Oligosaccharides derived from dragon 
fruit (DFO) are a mixture of fructo-oligosaccharides (FOS), and have prebiotic properties that increase beneficial 
bacteria in vitro. This study aimed to investigate changes in gut microbiota in the colon of mice fed a diet supplemented 
with DFO. Treatment groups were fed 100, 500, and 1000 mg/kg of DFO, 1000 mg/kg FOS and distilled water. The 
results showed that DFO did not change the body weight of mice, but altered microbiota in the proximal and distal 
colon. Populations of Blautia, Parabacteroides, and Bacteroides were among the highest proportions of bacteria 
represented after all treatments. Lactobacillus was also found in the proximal and distal colon. Moreover, qPCR results 
showed that Bifidobacteria increased in the distal colon of mice treated with 100 and 1000 mg/kg DFO for 14 days, 
while Lactobacilli increased in the proximal colon of mice treated with 500 mg/kg DFO for 7 days. In contrast, 
Enterococci decreased in the proximal colon of mice that were given 100, 500, and 1000 mg/kg of DFO and 1000 mg/
kg of FOS for 14 days. These results suggested that DFO is capable of increasing populations of beneficial bacteria 
while decreasing populations of some other bacteria.
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ABSTRAK
Oligosakarida prebiotik digunakan sebagai suplemen untuk menambahbaik kesihatan kolon. Oligosakarida yang 
diambil daripada buah naga (DFO) adalah campuran frukto-oligosakarida (FOS) dan mempunyai sifat prebiotik yang 
meningkatkan bakteria berfaedah secara in vitro. Kajian ini bertujuan untuk mengkaji perubahan dalam mikrobiota 
usus pada kolon tikus diberi makan diet disuplementasi dengan DFO. Kumpulan rawatan diberi makan 100, 500 dan 
1000 mg/kg DFO, 1000 mg/kg FOS dan air suling. Keputusan menunjukkan DFO tidak mengubah berat tikut tetapi 
meminda  mikrobiota pada proksimal dan kolon distal. Populasi Blautia, Parabacteroides dan Bacteroides adalah 
antara perkadaran tertinggi bakteria selepas rawatan. Lactobacillus juga ditemui pada proksimal dan kolon distal. 
Tambahan lagi, keputusan qPCR menunjukkan bahawaa Bifidobacteria meningkat dalam kolon distal tikus dirawat 
dengan 100 dan 1000 mg/kg DFO untuk 14 hari, manakala Lactobacilli meningkat dalam kolon distal tikus dirawat 
dengan 500 mg/kg DFO untuk 7 hari. Secara kontra, Enterococci menurun dalam kolon distal tikus yang diberi makan 
100, 500 dan 1000 mg/kg DFO serta 1000 mg/kg FOS untuk 14 hari. Keputusan ini menunjukkan bahawa DFO 
berupaya untuk meningkatkan populasi bakteria berfaedah sambil menurunkan populasi bakteria lain. 
Kata kunci: Buah naga; kolon; mikrobiota usus; oligosakarida prebiotik 
INTRODUCTION
Prebiotics are non-digestible nutrients, such as inulin, 
fructo-oligosaccharide (FOS), isomalto-oligosaccharide, 
xylo-ol igosaccharide,  lactulose,  and galacto-
oligosaccharide (GOS), which can be found in natural 
foods like chicory, agave, artichoke, grains, milk, and 
dragon fruit (Gibson & Rastall 2006; Wichienchot et al. 
2010). Prebiotics increase the growth of bifidobacteria and 
lactobacilli in the human intestine and provide health 
benefits to both humans and animals as they affect the 
composition of microbiota in the gut and improve the 
gastrointestinal system of hosts (Binn 2013; Femia et al. 
2010; Gibson et al. 2010; Mandal et al. 2009; Sabater-
Molina et al. 2009; Vamanu & Vamanu 2010; Xu et al. 
2009; Yeo & Liong 2010). Furthermore, prebiotics are able 
to prevent infectious diarrhea, antibiotic-associated 
diarrhea, traveler’s diarrhea, irritable bowel syndrome 
(IBS) and colitis, and also reduce cholesterol levels (Binn 
2013; Guarner & Malagelada 2003; Patel & Goyal 2012). 
Prebiotics have been used as supplements in animal 
food. A previous study showed that mannan-oligosaccharide 
increased the villus length of the duodenum and jejunum 
as well as the crypt depth of the duodenum and ileum of 
broiler chickens (Pelicano et al. 2005). Moreover, the 
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combination of chicory prebiotic and Enterococcus 
faecium could enhance growth and increase the length of 
the villus and crypt of broiler chickens (Awad et al. 2008). 
In addition, oligosaccharides extracted from vegetables 
and fruits are useful prebiotics that effectively promote 
beneficial bacteria and inhibit harmful bacteria (Gibson & 
Roberfroid 1995; Thammarutwasik et al. 2009; Wichienchot 
et al. 2010).
The dragon fruit (Hylocereus undatus (Haw.)) is a 
nutrient-rich fruit that contains high levels of beta-carotene, 
lycopene, and vitamin E (Charoensiri et al. 2009). The 
unsaturated fatty acids in oil extracted from dragon fruit 
seeds is composed of about 50 % essential fatty acids (48 
% linoleic acid (C18:2), and 1.5 % linolenic acid (C18:3)) 
(Ariffin et al. 2008). Glucose, fructose, and oligosaccharides 
are also present in dragon fruit (Wichienchot et al. 2010). 
Powdered dragon fruit oligosaccharide (DFO) mainly 
consists of fructo-oligosaccharide (DP 2 - 5) and fructose 
(Wichienchot & Pansai 2013). An in vitro study showed 
that although DFO was not digested by human gastric 
juices, it could increase the growth of Lactobacillus and 
Bifidobacterium while reducing the growth of Bacteroides 
and Clostridium (Dasaesamoh et al. 2016a; Wichienchot 
et al. 2010). In addition, a fecal fermentation experiment 
showed that increased levels of short chain fatty acids 
inhibited the growth of carcinogenic colon cells (Caco-2), 
thus DFO decreased the risk of colon cancer (Dasaesamoh 
et al. 2016a). However, the effects of DFO on the 
composition of gut microbiota in the colon of healthy mice 
are still unknown. This paper presents an in vivo study 
conducted to identify changes in gut microbiota in mice 
treated with DFO.
MATERIALS AND METHODS
ANIMALS
Inbred mice (strain BALB/cMlac, 5 weeks old and 
weighing 20 - 21 g) were obtained from the National 
Laboratory Animal Center, Mahidol University, Thailand. 
All mice were reared under controlled conditions 
(temperature 23 - 25 ºC, relative humidity 50 - 55 % and 
12:12 h light/dark cycle) at the Southern Laboratory 
Animal Facility, Prince of Songkla University, Thailand. 
Mice were given commercial animal food (S.W.T., 
Thailand) and free access to filtered water. The experimental 
protocol was approved by the Institutional Animal Care 
and Use Committee of Prince of Songkla University 
(project license number: MOE 0521.11/1410 Ref. 
16/2016).
EXTRACTION OF OLIGOSACCHARIDES                          
FROM DRAGON FRUITS
DFO was supplied by a research group at the Interdisciplinary 
Graduate School of Nutraceutical and Functional Food, 
Prince of Songkla University. White-fleshed dragon fruit 
was extracted using 80% ethanol at ambient temperature 
(28 ± 2 °C). Ethanol was then removed by distillation using 
a rotary evaporator operating at 175 mbar, 60 °C, and 45 
rpm. The dragon fruit extract was diluted 1:1 with distilled 
water, then redistilled to remove residual ethanol, and 
adjusted to 20˚Brix. Glucose and fructose were removed 
from the extract by yeast fermentation at room temperature 
(28 ± 2 °C) for 48 h with a 5% (v/v) inoculum of 
Saccharomyces cerevisiae strain BCC 12652. The 
fermented broth was filtered through cheesecloth to remove 
suspended solids (> 500 µm) including yeast pellets. The 
filtered broth was centrifuged at 10,000 × g at 4 °C to 
completely separate small solid particles and yeast cell 
debris. The purified supernatant was concentrated by rotary 
evaporator and spray dried to obtain DFO powder 
(Dasaesamoh et al. 2016b; Wichienchot et al. 2010). The 
chemical composition and oligosaccharide content of the 
obtained DFO powder were analyzed by AOAC (The 
Association of Analytical Chemists) method and HPAEC-
PAD, respectively (Table 1) (Wichienchot & Pansai 2013). 
The dried DFO powder was kept at -20 °C until use.
DFO TREATMENT AND COLLECTION                                        
OF GUT CONTENTS
Fifty mice were seperated into a 7-day treatment group of 
25 individuals and a 14-day treatment group of 25 
individuals. Both groups were then divided into five 
subgroups of five individuals which were all given access 
to commercial food. Additionally, the diet of each treatment 
group of five mice was supplemented differently by the 
administration (P.O.) of distilled water (DW), 100 mg/kg 
of DFO (DFO100), 500 mg/kg of DFO (DFO500), 1000 
mg/kg of DFO (DFO1000), or 1000 mg/kg of FOS 
TABLE 1. Chemical composition and oligosaccharide content of DFO powder (Wichienchot & Pansai 2013)
Composition Amount in 100 g powder (g)
Carbohydrate
Oligosaccharide (DP2-5)
Fructose
91.6
71.5
20.1
Protein 1.8
Fat 0.1
Ash 2.2
Moisture 4.3
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(FOS1000). FOS was used as a positive control at the same 
concentration used in a previous study that changed the 
populations of Enterococci, Enterobacteriaceae, 
Bifidobacteria and Lactobacilli in the cecum of mice (Pan 
et al. 2009). Body weight was recorded every day prior to 
the start of the experiment. Body weight change was 
calculated based on the change of body weight before and 
after the treatments. At the end of treatments, mice were 
anesthetized by intraperitoneal injection of 70 mg/kg 
thiopental sodium (Anesthal®), then the abdominal cavity 
was dissected and the entire colon was removed. The mice 
were then immediately euthanized. The removed colons 
were sectioned into proximal (3 cm distal to the cecum) 
and distal (3 cm proximal to the rectum) segments. Gut 
contents were collected in autoclaved microcentrifuge 
tubes and kept at -80 °C until use.
DNA EXTRACTION, PCR, AND ILLUMINA MISEQ
Before extraction of DNA, collected gut contents were 
homogenized in 200 μL Buffer A solution (100 mM 
Tris-HCl, 100 mM ethylenediaminetetraacetic acid 
[EDTA], 100 mM NaCl, and 0.5 % sodium dodecyl 
sulfate [SDS], pH 7.5) in a 1.5 mL tube and incubated 
at 65 °C for 30 min. The incubated homogenate was 
then mixed with 400 μL of LiCl/KAc solution (5 M 
potassium acetate: 6 M lithium chloride = 1:2.5), 
incubated on ice for 10 min and centrifuged for 15 min 
at 15000 rpm. After centrifugation, 500 μL of the 
supernatant was transferred to a new tube, mixed with 
300 μL isopropanol, and centrifuged for 15 min at 
15,000 rpm. Lastly, the supernatant was removed, the 
precipitate was washed with 70% ethanol, dried, and 
resuspended in 100 uL of MilliQ. All DNA samples were 
kept at -30 °C until used to amplify the 16S rRNA gene.
The V3-V4 hypervariable region of the bacterial 16S 
rRNA gene was amplified using 2× KAPA HiFiHotStart 
Ready mix DNA polymerase (Kapa Biosystems Ltd., 
London, UK) and primers with overhang adapter sequences 
(forward primer: 5’–TCGTCGGCAGCGTCAGATGTGTA 
TAAGAGACAGCCTACGGGNGGCWGCAG–3’, and 
reverse primer: GTCTCGTGGGCTCGGAGATGTGT 
ATAAGAGACAGGACTACHVGGGTATCTAATCC-3’) 
(Johnston et al. 2017). Cycle conditions were 3 min at 95°C 
followed by 25 three-temperature cycles (30 s at 95 °C, 30 
s at 55 °C, and 3 min at 72 °C), then a final extension of 
72 °C for 5 min. Libraries were purified using AMPure XP 
beads (LABPLAN; Naas, Ireland) in accordance with the 
Illumina 16S metagenomics sequencing library protocol. 
Dual Indices from the Illumina Nextera XT index kit 
(Illumina, San Diego, USA) were added to the target 
amplicons in the second PCR using 2× KAPA HiFi HotStart 
Ready mix DNA polymerase (Kapa Biosystems Ltd., 
London, UK) under the following conditions: 3 min at 95 
°C followed by 9 three-temperature cycles (30 s at 95 °C, 
30 s at 55 °C and 3 min at 72 °C), then a final extension 
of 72 °C for 5 min. Libraries were purified using AMPure 
XP beads (LABPLAN; Naas, Ireland). 
The barcoded amplicon libraries were combined into 
a single pool. The library pool was diluted and denaturated 
according to the Illumina Miseq library preparation guide. 
Sequencing was conducted on the Illumina Miseq using 
the 600 cycle Miseq reagent kit (version 3), and produced 
paired 301-bp reads. All sequencing data produced in this 
study were deposited in the NCBI SRA repository and are 
available via series accession number PRJNA516321.
METAGENOMIC ANALYSIS
Paired-end read sequences generated from Illumina Miseq 
were processed using Illumina 16S Metagenomics 
(version 1.0.1) workflow in Base Space-Illumina (https://
basespace.illumina.com/). Each read was blasted against 
the Illumina-curated version of the Greengenes database 
( g r e e n g e n e s . s e c o n d g e n o m e . c o m / d o w n l o a d s /
database/13_5) to determine the operational taxonomic 
units (OTUs) which corresponded to the 16S rRNA gene 
sequences. Taxa which did not conform enough to further 
classification, such as ‘unclassified at Kingdom level’ and 
‘Viruses’, were excluded from subsequent diversity 
analysis. OTU richness, Shannon-Weiner and Simpson 
diversity indices and evenness based on genera of bacteria 
were calculated. 
QUANTITATIVE POLYMERASE CHAIN                         
REACTION (qPCR)
qPCR of bacterial 16S rDNA of total bacteria, Lactobacilli, 
Bifidobacteria, and Enterococci was performed using a 
qPCR machine (LineGene 9600 Plus, Bioer, China) and 
SensiFAST SYBR No-ROX Kit (Bioline). PCR 
amplification protocols used the following primer sets to 
determine the total number of bacteria (forward 
5’-AGACACGGTCCAGACTCCTAC-3’; reverse 
5’-TTTACGGCGTGGACTACCAG-3’), the total number 
of Lactobacilli (FW 5’-CGATGAGTGCTAGGTGTTGGA 
-3’; RV 5’-CAAGATGTCAAGACCTGGTAAG-3’), the 
total number of Bifidobacteria (LM26 5’-GATTCT 
GGCTCAGGATGAACGC-3’; Bif228 5’-CTGATAGG 
ACGCGACCCCAT-3’), and the total number of 
Enterococci (ECF 5’-AGAAATTCCAAACGAACTTG-3’; 
ECR 5’-CAGTGCTCTACCTCCATCATT-3’). All 
reactions took place under the same conditions: 3 min at 
95 °C, and 40 two-temperature cycles (5 s at 95 °C and 30 
s at 60 °C) (Fu et al. 2006; He & Jiang 2005; Kaufmann 
et al. 1997; Matsuki et al. 2004; Peerakietkhajorn et al. 
2015). 
STATISTICAL ANALYSIS
Daily body weight, body weight change, and amount of 
bacteria were presented as means ± standard error (SE). 
All data were tested with one-way ANOVA followed by 
Tukey’s honestly significant difference test at p ˂ 0.05 to 
compare with the control group. The statistical analyses 
were performed using the R statistical program R 3.5.2 
(The R Core Team 2013).
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RESULTS
EFFECTS OF DFO ON BODY WEIGHT OF MICE
The initial body weight of mice was 20.0 ± 0.0 g. At the 
end of the 7 day-treatments, body weight of all groups had 
increased to 22.2 ± 0.7 (DW), 23.6 ± 1.1 (DFO100), 24.4 
± 0.8 (DFO500), 22.2 ± 0.4 (DFO1000), and 23.8 ± 0.7 g 
(FOS1000). At the end of the 14-day treatments, body 
weight of all groups had increased to 24.0 ± 1.0 (DW), 
22.0 ± 1.2 (DFO100), 24.0 ± 1.0 (DFO500), 24 ± 1.0 
(DFO1000), and 24.0 ± 1.0 g (FOS1000). The body weight 
of mice in 7- and 14-day treatments was not significantly 
different among all treatments (p > 0.05, Figure 1(A) and 
1(B)). Their body weight changes were also not significantly 
different (p > 0.05, Figure 1(C)). 
EFFECTS OF DFO ON GUT MICROBIOTA IN PROXIMAL 
AND DISTAL COLON
A total of 6,268,538 raw data reads were generated from 
Illumina Miseq. About 5,683,885 high-quality reads 
remained after trimming and filtering. The range of high-
quality reads per sample was 218,376 to 456,208.
The total OTU richness at the genus level in the 
proximal colon of treated mice was estimated from 16S 
metagenomics results. In the 7-day treatment groups DW, 
DFO100, DFO500, DFO1000, and FOS1000, the OTU 
richness were 277, 270, 303, 280, and 284, respectively 
(Table 1). The dominant bacteria included Blautia (19 - 31 
%), Parabacteroides (22 - 31 %), Bacteroides (7 - 13 %) 
and Lactobacillus (2 - 14 %) (Figure 2(A)). Shannon-
Wiener and Simpson diversity indices were similar in all 
7-day treatments groups (2.376 - 2.513 and 0.143 - 0.169, 
respectively). The range of evenness of bacteria in the 
proximal colon at the end of 7-day treatments was from 
0.416 to 0.447 (Table 2). 
The bacterial composition in the proximal colon at the 
end of the 14-day treatments was similar to that of the 
7-day treatments. The dominant bacteria included Blautia 
(15 - 25 %), Parabacteroides (13 - 21 %), Bacteroides (5 
- 10 %), and Lactobacillus (1 - 8 %) (Figure 2(B)). OTU 
richness at the genus level in the proximal colon of mice 
from the 14-day treatment groups DW, DFO100, DFO500, 
DFO1000 and FOS1000 were 277, 283, 267, 279, and 258 
OTUs, respectively (Table 2). The Shannon-Wiener and 
Simpson diversity indices for these groups ranged from 
FIGURE 1. Body weight and body weight change of mice treated with DW, DFO and FOS for 7 and 14 days. Line graphs show the 
body weight of mice treated with DW, DFO and FOS for 7 days (A) and 14 days (B). Bar graphs show the body weight change of 
mice treated with DW, DFO and FOS for 7 and 14 days (C)
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FIGURE 2. The composition and relative OTU abundance of microbiota. Bar graphs show composition and relative OTU 
abundance of microbiota in the proximal colon of mice treated with DW, DFO and FOS for 7 days (A) and 14 days (B), and in the 
distal colon of 7-day-treatment mice (C) and 14-day-treatment mice (D)
2.516 to 2.625 and from 0.136 to 0.168, which were not 
dissimilar to the indices of the 7-day treatment groups. The 
evenness of bacteria ranged from 0.450 to 0.466. There 
was also a considerable increase in populations of other 
bacteria in the proximal colon at the end of 14-day 
treatments.
In the distal colon, Blautia (7 - 22 %), Parabacteroides 
(27 - 41 %), Bacteroides (10 - 14 %) and Lactobacillus (9 
- 16 %) were the dominant bacteria in the 7-day treatment 
groups (Figure 2(C)). The OTU richness of bacteria in 
distal colon of mice from the 7-day treatment groups DW, 
DFO100, DFO500, DFO1000, and FOS1000 were 311, 
246, 281, 261, and 295 OTUs, respectively (Table 2). The 
Shannon-Weiner diversity indices ranged from 2.054 to 
2.486 while Simpson diversity indices ranged from 0.144 
to 0.225. The range of evenness of bacteria in all the 7-day 
treatment groups was from 0.369 to 0.437. 
Bacterial dominance in the distal colon of mice treated 
for 14 days showed a similar profile to that of mice treated 
for 7 days (Blautia (6 - 17 %), Parabacteroides (13 - 22 
%), Bacteroides (3 - 11 %), and Lactobacillus (3 - 16 %)) 
(Figure 2(D)) but the proportion of other bacteria 
considerably increased in the distal colon of mice treated 
for 14 days. The total OTU richness at genus level in the 
distal colon of the 14-day treatment groups DW, DFO100, 
DFO500, and DFO1000, and FOS1000 were 234, 269, 
262, 264, and 289 OTUs, respectively (Table 2). The 
Shannon-Wiener and Simpson diversity indices of the 14-
day treatment groups were 2.343 - 2.726 and 0.120 - 0.197, 
respectively. The evenness of bacteria was similar in all 
treatments (0.421 - 0.487).
QUANTITIES OF TOTAL BACTERIA, BIFIDOBACTERIA, 
LACTOBACILLI AND ENTEROCOCCI
The qPCR results showed that total bacteria in the proximal 
colon of mice treated for 7 days was approximately 109 - 
1010 cells/mg DNA, while total bacteria in the distal colon 
of these mice was approximately 1010 - 1011 cells/mg DNA 
(Figure 3(A) and 3(B)). The numbers of total bacteria in 
the proximal and distal colon of mice treated for 7 days 
were not significantly different from the control  (p > 0.05). 
The numbers of total bacteria in both proximal and distal 
colons of mice treated with DFO and FOS for 14 days were 
also not significantly different from the control 
(approximately 1010 - 1011 cells/mg DNA) (p > 0.05, Figure 
3(C) and 3(D)). 
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The concentration of Bifidobacteria in the proximal 
colon of mice treated with DFO and FOS for 7 and 14 days 
were approximately 107 - 108 cells/mg DNA (Figure 3(E) 
and 3(F)). These numbers were not significantly different 
from the control (p > 0.05). Similarly, in the distal colon 
of mice treated with DFO and FOS for 7 days, the number 
of Bifidobacteria was not significantly different from the 
control (Figure 3(G)). However, in the 14-day treatment 
groups DFO100 (6.69 ± 0.90 × 108 cells/mg DNA) and 
DFO1000 (4.85 ± 1.64 × 108 cells/mg DNA), the 
concentration of Bifidobacteria in the distal colon was 
significantly higher than the control (7.27 ± 3.25 × 107 
cells/mg DNA) (Figure 3(H)). 
Lactobacilli in the proximal colon of mice treated with 
DFO500 for 7 days (2.23 ± 0.61 × 109 cells/mg DNA) was 
slightly higher than the control (5.88 ± 4.96 × 107 cells/
mg DNA) (p<0.05, Figure 3(I)) but the number of 
Lactobacilli in the proximal colon of all 14-day treatment 
groups was not significantly different from the control (p 
> 0.05, Figure 3(J)). In the distal colon of mice treated for 
7 and 14 days, Lactobacilli numbers were not significantly 
different from the control (p > 0.05, Figure 3(K) and 3(L)).
In this study, numbers of Enterococci were significantly 
lower in the proximal colon of mice from the 14-day 
treatment groups DFO100, DFO500, DFO1000, and 
FOS1000 (p < 0.05, Figure 3(N)). However, no reduction 
occurred in the proximal colon of mice in the 7-day 
treatment groups DFO100, DFO500, DFO1000, and 
FOS1000 (p > 0.05, Figure 3(M)). Numbers of Enterococci 
in the distal colon of mice treated for 7- and 14-days were 
not different from the control (Figure 3(O) and 3(P)).
DISCUSSION
The effects of prebiotic DFO on gut microbiota in the 
proximal and distal colon of mice were investigated. The 
results showed that DFO did not affect the body weight of 
the mice, but could change the composition of microbiota 
in the proximal and distal colon. The V3-V4 hypervariable 
region of the bacterial 16S rRNA gene was sequenced by 
Illumina-Miseq. Blautia, Parabacteroides, Bacteroides. 
and Lactobacillus were the dominant bacteria in both 
proximal and distal colons. Blautia made up the highest 
proportion of microbiota in the proximal colon, whereas 
in the distal colon Parabacteroides was dominant. These 
commensal bacteria are commonly found in the human 
and rodent gut (Rezzonico et al. 2011; Salminen et al. 
1998).
TABLE 2. OTU richness, evenness, Shannon-Weiner and Simpson diversity indices of microbiota in proximal and distal colon of 
mice treated with DW, DFO and FOS for 7 days and 14 days
Treatment Indices
OTU Richness 
(Genus-level)
Shannon-Wiener 
diversity index
Simpson diversity 
index
Evenness
7-day treatment 
proximal colon
DW 277 2.513 0.148 0.447
DFO 100 270 2.451 0.169 0.438
DFO 500 303 2.376 0.167 0.416
DFO 1000 280 2.450 0.163 0.435
FOS 1000 284 2.510 0.143 0.444
distal colon
DW 311 2.413 0.168 0.420
DFO 100 246 2.226 0.198 0.404
DFO 500 281 2.308 0.173 0.409
DFO 1000 261 2.054 0.225 0.369
FOS 1000 295 2.486 0.144 0.437
14-day treatment
proximal colon
DW 277 2.518 0.157 0.448
DFO 100 283 2.605 0.168 0.461
DFO 500 267 2.516 0.162 0.450
DFO 1000 279 2.625 0.136 0.466
FOS 1000 258 2.531 0.163 0.456
distal colon
DW 234 2.451 0.157 0.449
DFO 100 269 2.726 0.120 0.487
DFO 500 262 2.343 0.197 0.421
DFO 1000 264 2.505 0.138 0.449
FOS 1000 289 2.533 0.145 0.447
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To compare the bacteria of interest, we conducted 
qPCR to estimate the number of total bacteria, 
Bifidobacteria, Lactobacilli, and Enterococci. We found 
that Bifidobacteria tended to increase in the distal colon 
of mice treated with 100 mg/kg, and 1000 mg/kg DFO for 
14 days. The amount of Lactobacilli also increased in the 
proximal colon of mice that received 500 mg/kg DFO for 
7 days. These results suggest that DFO was utilized by 
Bifidobacteria and Lactobacilli, and enhanced their growth. 
This result was consistent with an in vitro study, which 
showed that DFO stimulated the growth of Bifidobacteria 
and Lactobacilli (Dasaesamoh et al. 2016a; Wichienchot 
et al. 2010). Fermentation products of Bifidobacteria and 
Lactobacilli include acetate, lactate, formate, and ethanol 
(Salminen et al. 1998). Formate and acetate are short-chain 
fatty acids, which are also energy sources for the host’s 
intestinal cells that in turn benefit the host’s health (Binn 
2013).
In the case of Enterococci, growth decreased in the 
proximal colon of mice treated with DFO100, DFO500, 
DFO1000, and FOS1000 for 14 days. Both DFO and FOS 
effectively depleted numbers of Enterococci. Most 
Enterococci found in the human colon are Enterococcus 
faecalis and Enterococcus faecium that act as commensal 
bacteria in the host (Gilmore et al. 2002).  However, 
Enterococcus faecalis can cause infection and harmful 
effects when the population increases. Enterococcus 
faecalis infections increase in patients suffering from 
inflammatory bowel disease (IBD) (Zhou et al. 2016). In 
this study, we used healthy mice to test the effects of DFO 
on the composition of gut microbiota. Although there was 
growth of Enterococci as commensal bacteria, its growth 
FIGURE 3. The bar graphs show the numbers of bacteria present in the colons of treated mice: Total bacteria in the proximal 
colon of mice treated with DW, DFO and FOS for 7 days (A) and 14 days (B), and in distal colon of 7-day-treatment mice (C) and 
14-day-treatment mice (D); Bifidobacteria in the proximal colon of mice treated with DW, DFO and FOS for 7 days (E) and 14 
days (F), and in the distal colon of 7-day-treatment mice (G) and 14-day-treatment mice (H); Lactobacilli in the proximal colon 
of mice treated with DW, DFO and FOS for 7 days (I) and 14 days (J), and in the distal colon of 7-day-treatment mice (K) and 
14-day-treatment mice (L); Enterococci in the proximal colon of mice treated with DW, DFO and FOS for 7 days (M) and 14 
days (N), and in the distal colon of 7-day-treatment mice (O) and 14-day-treatment mice (P). Asterisks above the bars indicate 
significant differences from control (Tukey’s honestly significant difference test, p < 0.05)
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was controlled by the other normal flora and therefore 
caused no serious illness in the mice. For further 
experiment, the IBD model with Enterococcus faecalis 
infection might be included to investigate and confirm that 
DFO can protect the host from harmful bacteria. The 
immunity of treated mice should also be observed to 
support the hypothesis that DFO balances microbiota to 
the benefit of the host’s health.
CONCLUSION
This study suggests that DFO has the ability to modulate 
the microbial composition in both the proximal and distal 
colons of mice. DFO treatment could also change the 
proportion of Lactobacilli and Enterococci in the proximal 
colon, and that of Bifidobacteria in the distal colon. Even 
though this study was carried out with healthy mice, the 
results showed that DFO efficiently increased the growth 
of beneficial bacteria (Bifidobacteria and Lactobacilli) in 
the colon while depleting the numbers of harmful bacteria, 
like Enterococci. 
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